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Outcomes of original and low-permeability Gore
Excluder endoprosthesis for endovascular
abdominal aortic aneurysm repair
William Tanski, III, MD, and Mark Fillinger, MD, Lebanon, NH
Objective: Because of concern about the percentage of enlarging abdominal aortic aneurysms (AAAs) after endovascular
repair with the Excluder device (W.L. Gore & Assoc, Inc, Sunnyvale, Calif), the graft material was modified to reduce its
permeability and released for commercial use in mid-2004. We studied all AAA repairs with Excluder endografts
performed at our institution, including the original-permeability (OP) version (n  99) and the low-permeability (LP)
version (n  48).
Methods: All patients were followed up with serial computed tomography (CT) angiography and three-dimensional (3D)
reconstruction. Morphologic measurements, including AAA diameter and 3D volume, were prospectively entered into a
database to evaluate changes in AAA size over time. Owing to the length of available follow-up for the LP version, the
primary end point was AAA size change at 6 and 12 months, evaluated by Mann-Whitney U test for unpaired samples.
Results: Preoperative and postoperative anatomy was similar in the two groups, including AAA diameter (OP, 5.6 1 cm;
LP, 5.8 2 cm; P .3), aortic neck length (OP, 21 1mm; LP, 22 2mm; P .9), postoperative aortic seal zone (OP,
18 1mm; LP, 16 1mm, P> .1) and iliac seal zone (OP, 33 1mm, LP 31 1mm, P .2). The rate of sac shrinkage
differed significantly. Orthogonal diameter measurements showed a significant difference in the rate of shrinkage by 12
months postoperatively (OP, 2.1  1 mm; LP, 5.1  1 mm; P  .01). By 3D volume, the rate of shrinkage was
considerably different between the two groups at both 6 and 12 months (12 months: OP,6% 1%; LP,20 4%; P
.0006). There was no enlargement by diameter in either group at 6 or 12 months postoperative. By standard volume
criteria, however, 12 of 99 patients in the OP group and one of 48 patients in the LP group had significant AAA
enlargement <12 months (P  .04). Of these, four of 12 patients in the OP group had enlargement without apparent
endoleak, even on delayed-contrast CT. The remainder had persistent type II endoleaks (8/12 in the OP group and 1/1
in the LP group). Multivariate analysis revealed graft permeability (P< .0001) and endoleak (P< .0001) as independent
factors in aneurysm size change. In the OP group long-term, the average AAA enlarged at later time points compared with
the prior scan: 24 months, 0.2%; 36 months, 0.2%; 48 months, 2%; and 60 months, 2% (P < .0002).
Conclusions: In early follow-up, the low-permeability Excluder device is associated with a significantly greater aneurysm
shrinkage rate than the original version. Clinically important enlargement also appears significantly different within 1
year of implantation. Despite these promising results, longer follow-up is needed to determine whether these differences
will persist. ( J Vasc Surg 2007;45:243-9.)Multiple clinical studies have demonstrated the safety
and efficacy of the original Gore Excluder endoprosthesis
(W.L. Gore & Assoc, Inc, Sunnyvale, Calif), and it was
commercially released in the United States in 2001.1,2
More recent long-term studies, however, have documented
higher rates of nonshrinkage and late sac expansion com-
pared with other commercially available endografts.3-6
Rates of abdominal aortic aneurysm (AAA) expansion ap-
pear to be increasing as the length of follow-up increases,
with expansion rates in at least 33% of aneurysms by 4 years
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distributed worldwide to date,6 this is a significant issue.
The cause of the potentially higher sac expansion rates
with the original Excluder device was not initially apparent.
In most cases, sac expansion occurred in the absence of
endoleak.4,5,7 Aneurysm enlargement without endoleak is
not rare and has been observed with multiple endovascular
devices,8-11 different fabric types,12 and even after open
repair,13,14 but the incidence of expansion without en-
doleak appeared higher with the original Excluder en-
dograft than with others.3-7 Explantation of the endograft
typically confirms an absence of endoleak and the presence
of gelatinous material within the sac, external to the en-
dograft.1,7,10,13-15 The natural history of continued sac
expansion without endoleak in patients with an Excluder
endograft is currently unclear but has led to a number of
conversions to open repair and has been associated with
aneurysm rupture with this device and others in rare cases. 10
After investigations suggested that graft material per-
meability might explain the sac expansion in a significant
number of cases, the expanded polytetrafluoroethylene mi-
crostructure was redesigned to reduce its porosity and
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This new low-permeability (LP) endograft became com-
mercially available in the United States in mid-2004.
Whether this modification alters aneurysm sac behavior
over time compared with the original-permeability (OP)
endograft remains unclear.
In the following report, we detail follow-up of all OP
and LP Excluder endograft implantations at our institu-
tion. Prior analysis of the enlarging aneurysms in the Gore
Excluder US Pivotal trial confirmed that three-dimensional
(3D) volume measurements detected aneurysm growth
much earlier than diameter measurements did.5 This 3D
method was used to evaluate the changes in aneurysm sac
size over time with the OP and LP versions of the Excluder
endograft. A detailed comparison of preoperative and post-
operative anatomy was performed according to computed
tomography (CT) scans, 3D reconstruction, and morpho-
logic measurements.
METHODS
All patients who underwent endovascular AAA repair
(EVAR) with an Excluder bifurcated endoprosthesis from
January 1999 to December 2005 at Dartmouth-Hitchcock
Medical Center (Lebanon, NH) were analyzed by using
data obtained from a prospectively maintained database
including morphometric 3D analysis. During this time
period, 150 patients had Excluder devices implanted in
clinical trials and commercial use (after 2001). These re-
pairs represent a subset of400 EVARs performed during
the same time period at our institution. Before mid-August
2004, all Excluder endografts had one material design, the
OP group, and all Excluder grafts placed thereafter were of
LP group.
Repairs that had components from other manufactur-
ers in addition to Excluder components (n  2) or had
atypical pathology (penetrating ulcer causing aneurysm,
Fig 1. Bench-top comparison of original permeability and low
permeability devices. Prostheses are soaked in alcohol before test-
ing to “wet out” the material, breaking down the expanded
polytetrafluoroethylene hydrophobic barrier, and then pressurized
with bovine serum. This process produces obvious transmigration
of serum in the original endoprosthesis construct, but not in the
low permeability endoprosthesis. Material permeability changed
from 0.233 gm/(min cm2) to 0.000 gm/(min cm2). (Figure
and data courtesy W.L. Gore Medical Products Division.)n  1) were excluded from this analysis, leaving 99 in theOP group and 48 in the LP group. All of these patients had
a preoperative CT scan, at least two postoperative CT scans,
and 3D reconstruction with validated measurements. Data
collection was approved by the Institutional Review Board
for human subjects atDartmouth-HitchcockMedical Center.
Imaging. Preoperative and postoperative imaging was
primarily spiral CT with 3D reconstruction and Computer
AidedMeasurement, Planning and Simulation (3D CAMPS)
software (Preview Medical Metrix Solutions, formerly
Medical Media Systems, West Lebanon, NH). Scanning
protocols covered a volume from the celiac to common
femoral arteries, using a 3D CAMPS technique that has
been previously published in detail.16-19
Patients with severe renal insufficiency but not receiv-
ing dialysis underwent magnetic resonance angiography
(MRA) to delineate the anatomy with 3D reconstruction
and also unenhanced CT because MRA does not detect or
display calcified plaque well. Alternate strategies included
gadolinium-enhanced CT or, more recently, acetylcysteine
prophylaxis and nonionic contrast agent in patients withmod-
erate renal insufficiency (serum creatinine, 2 to 3 mg/dL).
Electronic data from CTA or MRA were sent in Dicom
format for postprocessing (Medical Metrix Solutions), in-
cluding multiplanar reformats encompassing the entire vol-
ume of the scan in sagittal, coronal, and axial planes at
0.75-mm to 2-mm intervals and orthogonal reformats at
1-mm intervals. Measurements were performed using vali-
dated techniques, including electronic calipers, and stan-
dard measurement definitions, including Society for Vascu-
lar Surgery (SVS) Reporting Standards.20,21
Key anatomic measurements included maximum AAA
diameter change, with 5 mm considered significant, and
3D volume change measured from the lowest renal artery
to the aortic bifurcation and from the lowest renal artery to
the common iliac artery bifurcation to capture changes in
patients with iliac aneurysms. Diameters were measured
orthogonal to the vessel (ie, in a plane at a right angle to the
centerline of the lumen).
Methods for 3D volume used a standard 3D recon-
struction technique described previously,17-19 validated on
phantoms of known size and clinically on aortic aneurysms,
with an interobserver variability 5%. For 3D volume
changes, changes of 5% were considered significant ac-
cording to interobserver variability and SVS Reporting
Standards.18,20 Other morphometric variables included
neck length, diameter, and achieved apposition; initial sac
diameter; iliac length, diameter, and achieved apposition;
aortic neck angulation, device angulation over time; en-
doleak during interval being examined; and endoleak at any
time.
Spiral CT, 3D reconstruction images, and morphomet-
ric data for all patients were prospectively collected and
entered into a database for comparison of aneurysm mor-
phology over time. These data were used for patient eval-
uation and management purposes as standard-of-care.
Comparison of the OP and LP groups was performed
retrospectively for aneurysm size and other anatomic indi-
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repair.17,20,21
Operative technique. All EVARs were performed in
the operating room with a 12-inch digital C-arm fluoros-
copy unit (GE/OEC 9800, GE Medical Systems, Milwau-
kee, Wis; or initially, Philips BV 312, Philips Medical Sys-
tems, Santa Ana, Calif) and carbon fiber table. Completion
arteriography was always performed, with antegrade con-
trast injection at the proximal attachment site and separate
retrograde injection in both iliac arteries. Other injection
sites were used, as deemed necessary if endoleak was present
(junction injection, separate views), to rule out type I or
type III endoleak. Pressure measurements were typically
performed to ensure systemic pressure without pressure
gradients to the femoral level.
Patient follow-up. Patients participating in phase II
(Pivotal) or phase III (Continued Access) clinical trials
were seen at follow-up at 1, 6, and 12 months, with annual
visits thereafter. Interim visits were scheduled as clinically
indicated or per manufacturer recommendations for trial pa-
tients. Each visit included a patient interview, review of sys-
tems, physical examination, determination of ankle-brachial
index, and CT scan with 3D reconstruction including
computer-aided volume measurements. Abdominal radio-
graphs (4 views) were used to evaluate for fracture. Addi-
tional studies, including duplex ultrasonography and an-
giography, were performed as clinically indicated.
Follow-up was nearly identical after the OP device
became commercially available, with the exception that ankle-
brachial indices were not routinely performed and patients
without detectable endoleak on postoperative scan at 1
month were more likely to have a CT scan at 6 months or
12 months, rather than both. All patients had at least two
postoperative scans, and one at either 6 or 12 months
(within a 3-month window). Scans at 12 months were not
done in 20 patients in OP group or in 11 in the LP group.
Median follow-up was 33.4 months in the OP group and
11.3 months in the LP group.
Statistical analysis. Anatomic measurements were an-
alyzed using the Statview statistical software package (SAS
Institute, Cary, NC). Nominal variables were compared by
2 or the Fisher exact test. Continuous variables were
analyzed using parametric and nonparametric methods.
Frequency distribution suggested that the data approxi-
mated a normal distribution within reason considering the
sample size, and thus a t test was performed for preoperative
demographic variables. For size change at 6 and 12months, a
repeated measures analysis of variance with one between
factor and one within factor was used to account for re-
peated measures. This demonstrated that graft type was the
predominant effect (see Results).
We also used a nonparametric method for the end
points of AAA size at 6 and 12 months so that a normal
distribution was not necessary to the results, choosing the
Mann-Whitney U test for unpaired samples, with correc-
tion for multiple comparisons implying P .025 should be
used for significance rather than P .05. The nonparamet-ric test returned very nearly the same P value. For simplicity,
we report the values for the nonparametric test.
Variables are reported as mean standard error, unless
stated otherwise. Multivariate logistic regression analysis
was performed for key variables, including all that were
significant by univariate analysis. The primary outcome
variable (sac size change) was categorized into quartiles for
the regression analysis, as no aneurysm grew 5 mm in
diameter in either group within the first year.
RESULTS
The OP and LP groups were comparable in terms of
patient characteristics, aneurysm size, and other anatomic
indices reported to be predictive of outcomes for the aneu-
rysm sac after endovascular repair (Table I). No statistically
significant differences were found for any of the key patient
characteristics associated with aneurysm expansion, such as
smoking, gender, hypertension, and systemic blood pres-
sure. A somewhat greater percentage of lower extremity
peripheral vascular occlusive disease was found in the OP
group, andmore LP patients had hyperlipidemia. Anatomic
variables were also very similar, including the key character-
istics related to initial aneurysm size and available length for
aortic and iliac attachment and sealing. Very small differ-
ences were noted in the aortic neck diameter and external
iliac diameter that reached statistical significance.
Aneurysm size change. Aneurysm size change was
evaluated relative to the initial preoperative CT scan and to
the 1-month scan. The time from the preoperative CT scan
to the operation was slightly longer in the OP group at
2.8 0.3 months compared with 1.9 0.3 months in the
LP group (P  .035). This may reflect time related to
clinical trial evaluation and device availability before com-
mercial release of the OP device. Aneurysm size changed
very little from the preoperative CT scan to the 1-month
postoperative CT scan and was statistically similar for the
two groups. The change in diameter was 0.5  0.3 mm
for the OP device compared with 0.3  0.4 mm for the
LP device (P  .11). Volume change from preoperative to
1month postoperative was also similar between the groups:
OP, 1.6%  1%, and LP, 0.5%  1% (P  .29 for
volume measured from lowest renal artery to the aortic
bifurcation, and similar for the renal-to-hypogastric vol-
ume, P  .55).
To eliminate the effect of aneurysm growth between
the preoperative CT and the procedure, AAA size change
was primarily evaluated relative to the postoperative CT
scan at 1 month. Aneurysm size change for diameter and
volume from 1 to 6 months and from 1 to 12 months is
shown in Fig 2 and Fig 3. On average, AAAs decreased in
size with both devices. By orthogonal diameter measure-
ments, there was no significant difference in the rate of shrink-
age at 6 months, but by 12 months, the rate of shrinkage
was statistically different (Fig 2). The rate of shrinkage by
volume was considerably different between the two groups
at both 6 and 12 months postoperatively, with more highly
significant P values for both intervals (Fig 3, shown for 3D
renal-to-hypogastric artery volume measurement). Data
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(not shown, P  .02 and P  .002).
Aneurysm enlargement. The incidence of aneurysm
enlargement was specifically evaluated to detect individual
aneurysm changes that might be masked by average trends
in each group. Using standard diameter threshold (5 mm
change), there was no enlargement in either group at the






(n  48) P
Patient characteristics*
Age, years 74.2  1 74.7  1 .72
Female gender (%) 36 27 .26
Coronary artery disease (%) 30 42 .21
Carotid artery occlusive
disease (%) 21 13 .22
Lower extremity PVOD† (%) 36 19 .05
Smoking history (%) 77 81 .35
Diabetes mellitus (%) 17 17 .94
Hyperlipidemia (%) 58 77 .03
Pulmonary disease (%) 32 27 .53
Hypertension (%) 82 90 .33
Systolic blood pressure 139  2 141  3 .77
Diastolic blood pressure 71  2 69  3 .53
Creatinine, mg/dL 1.1  .03 1.1  .07 .44
Aneurysm anatomy
Maximum AAA diameter,
mm‡ 56  1 58  2 .29
Volume (cm3)
Renal to aortic bifurcation§ 145  6 158  10 .22
Renal to hypogastric 162  6 178  11 .13
Aortic neck (mm)
Length, mm 21.4  1.1 21.8  1.7 .86
Diameter, mm 21.4  0.3 22.3  0.3 .05
15 mm from renal 21.9  0.3 22.9  0.4 .04
Iliac diameter (R&L)¶
Common iliac 13.9  0.6 13.9  0.6 .94
External iliac 7.7  0.1 8.3  0.2 .01
Renal-aortic bifurcation
length, mm# 125  1 126  2 .89
Renal-hypogastric length
(R&L), mm** 179  2 185  3 .06
Aortic neck-AAA angle,
degrees†† 143  2 141  2 .51
OP,Original permeability; LP, low permeability; PVOD, peripheral vascular
occlusive disease; AAA, abdominal aortic aneurysm; R&L, right and left.
Variables are reported as mean  standard error or percentages.
*Obtained from the past medical history in patient charts.
†Patients with ankle-brachial indices 0.9.
‡Measured in an orthogonal computed tomography reformat (at right angle
to the vessel) on 3D reconstructions.
§The 3D volume measured from the most distal renal artery to the aortic
bifurcation.
The 3D volume measured from the most distal renal artery to the most
proximal hypogastric artery (internal iliac artery).
¶The average for the entire nonaneurysmal length of the common iliac
artery, averaged for right and left side (not the attachment site diameter).
#The 3D lumen centerline length from renal artery to aortic bifurcation.
**The 3D lumen centerline length from the renal artery to common iliac
bifurcation (hypogastric artery).
††Aortic neck-AAA angle is measured from the infrarenal neck to the AAA
body.6-month or 12-month postoperative periods. By standardvolume criteria however (5% change in aneurysm volume),
12 of 99 patients in the OP group and one patient of the 48
in the LP group had significant enlargement within the first
12 months (P .04). Four of 12 patients in the OP group
(and none in the LP group) had aneurysm enlargement
without apparent endoleak, even on delayed-contrast CT.
Eight of 12 in the OP group and the single patient with
enlargement in the LP group had persistent type II en-
doleaks.
Attachment length and endoleak within the first
year of implantation. Variables that might explain the
postoperative aneurysm size changes were also evaluated.
No differences were found in aortic stent graft apposition
Fig 2. Abdominal aortic aneurysm (AAA) diameter change rela-
tive to the 1-month postoperative computed tomography scan. At
6 months, the change was original permeability (OP),1.6 0.3
mm, and low permeability (LP), 2.1  0.6 mm (P  .4), and at
12 months the change was OP, 2.1  0.6 mm, and LP 5.1 
1 mm (P  .01).
Fig 3. Abdominal aortic aneurysm (AAA) three-dimensional
(3D) volume change relative to the 1-month postoperative com-
puted tomography scan. In this case, 3D volume was measured
from the most distal renal artery to the most proximal internal iliac
artery. At 6 months the change was original permeability (OP),
4.9%  1%, and low permeability (LP) 11%  2% (P  .01),
and at 12 months the change was OP, 6.8%  2%, and LP,
19%  3% (P  .0006).(attachment length), iliac stent graft apposition, or en-
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LP group, but no significant difference whether evaluating
by sac enhancement of any kind (ie, any enhancement that
was not clearly calcification), or when evaluating using
endoleak of a defined size (Table II). A single proximal type
I endoleak occurred at implantation in the OP group, and
this was corrected with a proximal cuff before the 1-month
postoperative study. This was the only type I or III en-
doleak in either group at any time, and all endoleaks at 1
month and beyond were type II.
Other key clinical outcomes. No aneurysms ruptured
in either group during follow-up, and aneurysm-related
mortality was zero in both groups. No stent fractures
occurred in either group. One migration5 mm in the OP
group was detected at 18 months, and no migration has
been detected thus far in the LP group. There was no
significant difference in secondary interventions between
the two groups during the short period available for com-
parison. The OP group underwent four secondary proce-
dures within the first year (3 coil embolizations for type II
endoleak, 1 proximal cuff as described above), compared
with two in the 48 patients in the LP group (2 proximal
cuffs). Both aortic cuffs in the LP group were placed for
Table II. Key postoperative variables related to






(n  96) P
Attachment Site Measurements
Aortic neck
Apposition length, mm† 18.1  0.6 16.3  1.1 .13
Diameter 15 mm from
renal, mm 21.5  0.3 22.3  0.3 .09
Common iliac
Apposition length (R&L),
mm‡ 33.1  0.9 31.0  1.4 .20
Diameter (R&L), mm§ 12.1  0.1 13.2  0.2 .001
Aortic neck-AAA angle,
degrees 146  1 146  1 .72
Endoleak
Sac enhancement of any
kind (%)¶ 32 36 .40
Type II 2.5 cm3 (%) 6 11 .07
Type I and III (%) 0 0 .99
OP,Original permeability; LP, low permeability;R&L, right and left;AAA,
abdominal aortic aneurysm.
*Values shown for postoperative scans within the first year of device implan-
tation.
†The 3D lumen centerline length in which all cross-sections display 100%
circumferential apposition of the device to the aortic wall.
‡Also the length of 100% circumferential apposition, averaged for both
common iliac arteries.
§The average for the entire length of the common iliac artery, averaged for
right and left side (at the attachment site).
Measured from the infrarenal neck to the AAA body.
¶Indicates any nonthrombus density within the sac, no matter the size, and
is used to avoid speculation regarding significance of very small areas of
enhancement.devices with 5 mm circumferential neck apposition butno endoleak. One had an additional cuff and a Palmaz
stent, the other a cuff alone.
Multivariate analysis. Multivariable logistic regres-
sion analysis was performed for variables potentially related
to aneurysm size change, including all that were significant
by univariate analysis. Analysis included graft permeability,
gender, smoking status (current or not), hypertension,
hyperlipidemia, lower extremity occlusive disease, aortic
neck diameter, and iliac diameter. Of these variables, only
graft permeability (P  .0001) and endoleak (P  .0001)
were significantly associated with aneurysm size change
relative to the 1-month postoperative scan by both diame-
ter and volume. For sac size change determined by AAA
volume (but not diameter), the presence of lower extremity
arterial occlusive disease was also found to be a significant
factor by this analysis (P  .001).
Long-term sac behavior with the original perme-
ability device. Aneurysm size change during long-term
follow-up of the OP group is shown in Fig 4. On average,
most aneurysms initially demonstrated shrinkage with the
original device, then stabilized, but subsequently began to
enlarge in the 3-year to 5-year time frame. Trends for
diameter change over time were nearly identical. The LP
device has not been commercially available long enough for
a similar evaluation.
DISCUSSION
In this study, we found that the low-permeability Ex-
cluder device is associated with a significantly greater aneu-
rysm shrinkage rate than the original version, even with
relatively short follow-up. Perhaps more important, we
found a significant difference in the incidence of aneurysm
growth exceeding standard clinical thresholds for 3D vol-
ume. Our experience with the detection of aneurysm ex-
pansion indicates that 3D volume analysis will detect sig-
nificant differences within 6 months to 1 year, and typically
Fig 4. Abdominal aortic aneurysm (AAA) size change by time
interval for long-term follow-up of the original permeability
group. The change in three-dimensional volume is shown for size
change relative to the last computed tomography (CT) scan
(rather than change relative to the first postoperative scan) to
demonstrate changes in sac behavior over each specific time inter-
val. Diameter trends were very similar.1 year sooner than diameter changes.5,17 Other groups have
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eurysm size changes are detected more quickly and defini-
tively by 3D volume than by diameter. Despite this fact, the
shrinkage rate is statistically significant by diameter as well,
and given the available evidence, the differences in clinically
relevant sac expansion will likely be apparent using diame-
ter thresholds within 1 to 2 years.
The critical question is whether the differences found
here are due to material permeability or some other factor.
Notably, this single-center series contains two well-matched
groups, with no clinically important changes in practice in
the vascular anatomy selected for device implantation. Key
characteristics such as aneurysm size, neck length, attach-
ment vessel diameters, patient gender, smoking status,
blood pressure, and other parameters were quite similar in
the two groups even though half of the OP patients were
enrolled in clinical trials that enforced the device instruc-
tions for use.
This study suggests that type II endoleak can alter sac
behavior after EVAR, but with no difference in endoleak
presence, type, or size (even sac enhancement of any kind),
it seems clear that the difference cannot be explained by
endoleak. Moreover, multivariate analysis that included
endoleak revealed that graft permeability was significantly
and independently associated with aneurysm size change. It
is also notable that there was growth without apparent
endoleak in the OP group but not in the LP group.
In long-term follow-up of the OP group in this study,
the average AAA stabilized in volume from 1 to 3 years and
then began to enlarge at later time points, so longer follow-up
will be needed to definitively state that the improved per-
formance of the LP device will persist. Despite this, most of
the enlarging aneurysms in the Gore Pivotal trial could be
detected within 1 year using 3D volume,5 and there were
clear, statistically significant differences in aneurysm expan-
sion rates within the first year in our present study.
A recent in vivo animal study indicates that the endo-
tension associated with the original material is related to
transmission of pressure and serous fluid into the aneurysm
sac.23 The material change now makes the fabric essentially
impermeable, even with bench testing designed to make
the material “wet out” and become permeable (Fig 1).
Thus, it is expected that aneurysm enlargement owing to
material permeability has been eliminated with the newer
material.
One could reasonably question the significance of the
present findings. After all, we found no aneurysm-related
mortality, aneurysm ruptures, catastrophic device failures,
device deformation, or fractures in either group. There was
only a single case of migration in the OP group. The rate of
endoleak and secondary intervention in both groups was
comparable to the literature and well within accepted stan-
dards for endovascular series at large institutions. Some
have argued that if the incidence of enlargement with the
OP device was clinically important, there should have been
more aneurysm ruptures by now. Reports of rupture or
exploration of the aneurysm sac in these patients typically
does not reveal blood but rather a hygroma or gelatinoussubstance.1,7,10,14 This evidence has been used to suggest
that enhanced surveillance or other intervention is unnec-
essary for patients with sac enlargement in the absence of
endoleak with the Excluder device.
We believe the material change is clinically important,
however. With 30,000 devices distributed worldwide,6 and
at least 33% of treated aneurysms enlarging at 4 years,4-6 a
large number of patients and treating physicians will have to
decide what to do about aneurysm expansion. Although
the incidence of rupture for aneurysms enlarging without
endoleak appears low, some ruptures have been reported.10
A 3D morphologic analysis of the enlarging aneurysms
in the Excluder US Pivotal Clinical Trial found that aneu-
rysms expanding without detected endoleak enlarged at
half the rate of those with endoleak.5 It is possible that the
pressure generated frommaterial permeability is lower than
that of a typical type II endoleak, and thus it may take even
more time for the average moderate-sized aneurysm to
expand sufficiently to have substantial rupture potential.
Even if rupture risk is lower for these patients, the
expansion still makes follow-up more difficult. Patients are
understandably concerned about aneurysm expansion, and
the physician needs to determine whether the surveillance
interval should decrease. As the aneurysm expands, the
physician must determine an aneurysm size or rate of
expansion that makes further evaluation or intervention
appropriate. These values are currently unknown. One can
argue that a rupture might only produce spillage of hy-
groma into the abdomen. Anecdotal reports suggest rup-
ture in such a case may be managed successfully without
operation in selected cases, although at least one such
rupture may have been associated with a fatal bowel ob-
struction.10
Perhaps the most worrisome aspect of endotension, or
enlargement without apparent endoleak, is that it might
lend a false sense of security. A number of factors can cause
expansion with any endograft, including the original Ex-
cluder endograft.5,9,24-31 Attributing expansion to material
permeability can result in delayed diagnosis of other causes
of sac expansion, such as inadequate device attachment or
undetected endoleak. Open exploration of the sac for en-
dotension or enlargement without apparent endoleak re-
vealed a missed endoleak in 25% of cases in the Excluder
clinical trials.7
The expansion itself can cause other problems, such as
a progressively decreasing seal zone within the proximal
neck. This phenomenon has been seen at least once in this
series with the OP device during late follow-up, and at least
once in the 38 patients enlarging at 4 years in the Excluder
Pivotal trial.5
Finally, there is the issue of cost. Questions related to
material permeability with the OP device may lead to
routine delayed-contrast CT studies, additional MRA sur-
veillance, or angiographic evaluation when aneurysms ex-
pand. There is a significant cost to the increased patient
visits, time for patient education and counseling about the
issue, more frequent imaging and more extensive imaging.
Thus we believe that the results with the LP device are
JOURNAL OF VASCULAR SURGERY
Volume 45, Number 2 Tanski and Fillinger 249extremely important, and that continued study of the LP
device in a postmarket environment is also important. A
multicenter study of the LP device is currently being con-
ducted in the United States, with patient accrual completed
in mid-2006. It is hoped that study and others will answer
these important questions for the long-term.
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